Online inquiry

IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5702MR)

This product GTTS-WQ5702MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&CEACAM5 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4; NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 1048
UniProt ID P07766; P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5702MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3890MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ15172MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA T1h
GTTS-WQ6902MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ11111MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ13761MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ11690MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ15587MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ11778MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-3222
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW